Results 171 to 180 of about 76,287 (255)

Recent progress on the development of hydrogel‐based microneedles for transdermal drug delivery

VIEW, EarlyView.
This study provides a comprehensive and up‐to‐date analysis of recent progress in HMN technology, covering fundamental transdermal delivery mechanisms and design principles, biomaterials used in HMN fabrication, drug loading and release strategies, and emerging therapeutic applications.
Mohammad Muhtasim Ittisaf, Salman Farsi Taharat, Md. Sadek Miah, Hasan Tasnim Salehin, M. Azam Ali, Shoeb Ahmed   +5 more
wiley   +1 more source

Prescriptions for Glucagon-Like Peptide 1 Agonists (GLP-1RAs) Before Bariatric Surgery in the US. [PDF]

Ann Surg
Zion A, Segal JB, Mehta HB.
europepmc   +1 more source

Gut microbiota dysbiosis in the inflammatory pathogenesis of diabetic retinopathy

VIEW, EarlyView.
This graphical abstract illustrates how gut dysbiosis drives diabetic retinopathy through the gut‐retina axis, a process unfolding in three interconnected stages. First, in the gut, a decrease in beneficial bacteria and an increase in pro‐inflammatory taxa compromise the intestinal barrier, causing a “leaky gut” that allows LPS to translocate into the ...
Junyan Hu, Jingxiang Zhong
wiley   +1 more source

WITHDRAWN: Can glucagon like peptide-1 receptor agonists be beneficial for brain health?

Ballabio G, Mason A, Paz V, Dale C, Sofat R, Garfield V.   +5 more
europepmc   +1 more source

Oral Glucagon-Like Peptide-1 Receptor Agonists for Preventing Cardiorenal Complications. [PDF]

Curr Cardiol Rep
Odeleye V, Singh N, Gautam S, Shannon E, Bibb WM, McClure M, Paul TK.   +6 more
europepmc   +1 more source

Electrochemical aptasensors for ultrasensitive multiplexed detection: Towards a new era of precision diagnostics and environmental monitoring

VIEW, EarlyView.
Electrochemical aptasensors are emerging as powerful platforms for precision diagnostics and environmental monitoring, owing to their high selectivity, programmability and compatibility with miniaturised systems. However, their broader application is constrained by limited signal intensity and challenges in reliable multiplexed detection.
Azadeh Abdi, Ngoan Thi Thao Nguyen, Riccardo Zulli, Jacopo Giaretta, Fariba Dehghani, Syamak Farajikhah   +5 more
wiley   +1 more source

Perceptions of Glucagon-like Peptide 1 Receptor Agonists Among Individuals With Knee Osteoarthritis and Excess Weight: A Qualitative Study. [PDF]

ACR Open Rheumatol
Frier K, Dietl M, Aronson S, Dhani J, James K, Betensky D, Selzer F, Losina E, Katz JN, Kim JS, Weiss-Laxer NS.   +10 more
europepmc   +1 more source

Dipeptidyl Peptidase‐4 Inhibitor Use and Risk of Pemphigus Vulgaris and Foliaceus: A Retrospective Cohort Study Using Databases of the Korea National Health Insurance Claims and the National Health Screening Examination

The Journal of Dermatology, EarlyView.
ABSTRACT Although population‐based studies have reported an increased risk of bullous pemphigoid and pemphigus associated with dipeptidyl peptidase‐4 (DPP‐4) inhibitors, there is limited, well‐designed epidemiological evidence for pemphigus vulgaris (PV), which has only been supported by case reports thus far.
Jaein Lee, Jae Hyun Bae, Seokyung Hahn
wiley   +1 more source

Beyond Glycemic Control: Ocular Effects of Glucagon-like Peptide-1 Receptor Agonists. [PDF]

Vision (Basel)
Lixi F, Troisi M, Calabresi V, Giagoni A, Rossi C, Timofte-Zorila MM, Tarași TC, Vitiello L, Tomi MI, Gheorghe AG, Coco G, Lanzolla G, Giannaccare G.   +12 more
europepmc   +1 more source